Evidence map›Paper›PMID 41179658›Full record

ArticleFrontiers in oncology2025

B7-H7 knockdown suppresses the proliferation, metastasis, and drug resistance of B-cell non-Hodgkin lymphoma cells by inhibiting the PI3K/Akt pathway.

Aili Zhai, Qing Zou, Jiawei Yin, Shixin Ge, Xingfang Xiong, Tao Yan, Xiaoli Xie, Lijuan Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aili Zhai *Graduate Training Base of Jinzhou Medical University (Linyi People's Hospital), Linyi, Shandong, China.
Qing Zou *Department of Hematology, Linyi People's Hospital, Linyi, Shandong, China.
Jiawei YinLaboratory Animal Center, Linyi People's Hospital, Linyi, Shandong, China.
Shixin GeThe 11th Clinical College of Qingdao University (Linyi People's Hospital), Linyi, Shandong, China.
Xingfang XiongCentral Laboratory, Linyi People's Hospital, Linyi, Shandong, China.
Tao YanCentral Laboratory, Linyi People's Hospital, Linyi, Shandong, China.
Xiaoli XieCentral Laboratory, Linyi People's Hospital, Linyi, Shandong, China.
Lijuan WangGraduate Training Base of Jinzhou Medical University (Linyi People's Hospital), Linyi, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The activation of key immune regulatory factors is an important driving factor in the progression of therapeutic resistance in patients with B-NHL. As a novel immune regulatory factor of the B7 family, surface B7-H7 interacts with receptors on active T cells to promote tumor immune escape. However, investigations of B7-H7 on B-NHL are still lacking. Methods: Results: B7-H7 knockdown inhibited tumor growth Conclusions: Suppression of B7-H7 inhibited tumor progression and induced RTX sensitivity by suppressing the PI3K/Akt pathway.

Indexed as

B7-H7B-NHLcancer progressionPI3K/AKTresistancerituximab

Identifiers

PMID41179658
PMCPMC12571572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.